← All trials
NCT06465472
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2024
- Primary completion
- Aug 31, 2030
- Completion date
- Aug 31, 2030
- First posted
- Jun 18, 2024
- Last posted
- Jun 18, 2024
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiocodexLead sponsor
- ExystatCollaborator
- Monopar TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.